Citations

Clear

479 citation(s) found for "Tobias, JS".

Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Miloslavsky, Eli M. , Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Tchao, Nadia K., Viviano, Lisa, Ding, Linna , Sejismundo, Lourdes P., Mieras, Kathleen, Iklé, David , Jepson, Brett , Mueller, Mark, Brunetta, P., Allen, Nancy B., Keogh, Karina A., Peikert, Tobias, Stegeman, Coen A. , Ytterberg, Steven R. , Stone, John H., Brunetta, Paul , Specks, Ulrich , Merkel, Peter A. , Spiera, Robert , Fervenza, Fernando C. , Geetha, Duvuru , Kissin, Eugene Y. , Monach, Paul A.

Mayo Clinic

Arthritis & Rheumatism | June 10, 2013 | Volume: 65 | Issue: 9 | Pages: 2441-2449

10.1002/art.38044 | PMID 23754238 Get It

ObjectiveTo evaluate the reasons that complete remission is not achieved or maintained with original treatment in some patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) treated with rituximab (RTX) or with cyclophosphamide/azathioprine (CYC/AZA).MethodsThe Rituximab in AAV trial was a randomized, double‐blind, placebo‐controlled trial comparing the rate of remission induction among patients treated with RTX (n = 99) and patients treated with CYC followed by AZA (n = 98). Glucocorticoids were tapered over a period of 5 months. The primary outcome measure was lack of disease activity without glucocorticoid treatment at 6 months. To determine the most important reason for failure to achieve the primary outcome, 7 hierarchical categories of reasons were defined retrospectively (uncontrolled disease, adverse event leading to therapy discontinuation, severe flare, limited flare, Birmingham Vasculitis Activity Score for Wegener's Granulomatosis >0, prednisone treatment at any dosage, and other).ResultsAlthough remission (lack of disease activity) was achieved in 170 of the 197 patients (86%) in the first 6 months, the primary outcome measure was not achieved in 42%. There were 3 deaths. Twenty‐four percent of the patients failed to achieve the primary end point due to active disease: 10 (5%) experienced uncontrolled disease in the first month and 37 (19%) experienced flares after initial improvement. In the majority of such patients, treatment with blinded crossover or according to best medical judgment led to disease control. Ninety‐one percent of patients who had uncontrolled disease or experienced a severe flare had proteinase 3 (PR3)–ANCA. When patients with uncontrolled disease were excluded from analysis, those who were PR3‐ANCA positive were found to experience fewer flares when treated with RTX compared to CYC/AZA (8 of 59 [14%] versus 20 of 62 [32%]; P = 0.02). Neither ANCA titers nor B cell counts predicted disease flare.ConclusionCurrent treatment regimens are largely successful in controlling AAV, but in approximately one‐fourth of patients, active disease persists or recurs in the first 6 months despite treatment. PR3‐ANCA positivity is a risk factor for recurrence or persistence of severe disease. ANCA titers and B cell detectability are poor predictors of both disease relapse and disease quiescence in the first 6 months.
Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury
Eckle, Tobias , Hughes, Kelly, Ehrentraut, Heidi , Brodsky, Kelley S. , Rosenberger, Peter , Ravid, Katya , Weng, Tingting, Xia, Yang , Blackburn, Michael R. , Choi, Doo‐Sup , Eltzschig, Holger K.

Mayo Clinic

The FASEB Journal | April 19, 2013 | Volume: 27 | Issue: 8 | Pages: 3078-3089

10.1096/fj.13-228551 | PMID 23603835 Get It

The signaling molecule adenosine has been implicated in attenuating acute lung injury (ALI). Adenosine signaling is terminated by its uptake through equilibrative nucleoside transporters (ENTs). We hypothesized that ENT‐dependent adenosine uptake could be targeted to enhance adenosine‐mediated lung protection. To address this hypothesis, we exposed mice to high‐pressure mechanical ventilation to induce ALI. Initial studies demonstrated time‐dependent repression of ENT1 and ENT2 transcript and protein levels during ALI. To examine the contention that ENT repression represents an endogenous adaptive response, we performed functional studies with the ENT inhibitor dipyridamole. Dipyridamole treatment (1 mg/kg; EC 50 =10 μM) was associated with significant increases in ALI survival time (277 vs. 395 min; P <0.05). Subsequent studies in gene‐targeted mice for Ent1 or Ent2 revealed a selective phenotype in Ent2 ‐/‐ mice, including attenuated pulmonary edema and improved gas exchange during ALI in conjunction with elevated adenosine levels in the bronchoalveolar fluid. Furthermore, studies in genetic models for adenosine receptors implicated the A 2B adenosine receptor (Adora2b) in mediating ENT‐dependent lung protection. Notably, dipyridamole‐dependent attenuation of lung inflammation was abolished in mice with alveolar epithelial Adora2b gene deletion. Our newly identified crosstalk pathway between ENT2 and alveolar epithelial Adora2b in lung protection during ALI opens possibilities for combined therapies targeted to this protein set.—Eckle, T., Hughes, K., Ehrentraut, H., Brodsky, K. S., Rosenberger, P., Choi, D.‐S., Ravid, K., Weng, T., Xia, Y., Blackburn, M. R.Eltzschig, H. K., Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J. 27, 3078–3089 (2013). www.fasebj.org
New research article preparation guidelines
Kurth, Tobias , Dodick, David W. , Kurth, Tobias

Mayo Clinic

Cephalalgia | April 18, 2013 | Volume: 33 | Issue: 12 | Pages: 995-997

10.1177/0333102413483373 Get It

Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis
Finkielman, Javier D., Schroeder, Darrell R. , Hoffman, Gary S., Clair, E. William St. , Davis, John C. , McCune, W. Joseph, Lears, Andrea, Ytterberg, Steven R. , Hummel, Amber M., Viss, Margaret A., Peikert, Tobias, Stone, John H. , Merkel, Peter A. , Spiera, Robert , Specks, Ulrich , Schroeder, Darrell

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 147 | Issue: 9 | Pages: 611-619

10.7326/0003-4819-147-9-200711060-00005 | PMID 17975183 Get It

ECG-Gated 16-MDCT of the Coronary Arteries: Assessment of Image Quality and Accuracy in Detecting Stenoses
Heuschmid, Martin, Kuettner, Axel, Schroeder, Stephen, Trabold, Tobias, Feyer, A, Seemann, Marcus D., Claussen, Claus D. , Kopp, Andreas F., Kuzo, Ronald S.

Mayo Clinic

American Journal of Roentgenology | February 28, 2013 | Volume: 184 | Issue: 5 | Pages: 1413-1419

10.2214/ajr.184.5.01841413 | PMID 15855088 Get It

Genome-wide association study of survival in patients with pancreatic adenocarcinoma
Wu, Chen , Steplowski, Emily, Brotzman, Michelle, Xu, Mousheng, Mudgal, Poorva, Ámundadóttir, Laufey T. , Arslan, Alan A. , Bueno‐de‐Mesquita, H. Bas, Gross, Myron D., Helzlsouer, Kathy J., Jacobs, Eric J. , Petersen, Gloria M. , Zheng, Wei , Buring, Julie E. , Canzian, Federico , Cao, Guangwen , Duell, Eric J. , Elena, Joanne W. , Gaziano, J. Michael , Giovannucci, Edward L. , Hallmans, Göran, Hutchinson, Amy , Hunter, David J., Jenab, Mazda , Jiang, Guoliang , LaCroix, Andrea Z. , Li, Zhaoshen , Mendelsohn, Julie B., Panico, Salvatore , Patel, Alpa V. , Qian, Zhi Rong , Ríboli, Elio , Sesso, Howard D. , Shen, Hongbing , Shu, Xiao‐Ou , Tjønneland, Anne , Tobias, Geoffrey S. , Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala , Wactawski‐Wende, Jean , Wang, Chengfeng , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Hartge, Patricia, Fuchs, Charles S. , Lin, Dongxin , Wolpin, Brian M. , Kraft, Peter , Stolzenberg‐Solomon, Rachael Z. , Kooperberg, Charles , Albanes, Demetrius , Boutron‐Ruault, Marie‐Christine , Khaw, Kay‐Tee , Chanock, Stephen Jacob , Amundadottir, Laufey , Duell, Eric J , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Shu, Xiao-Ou , Visvanathan, Kala , Jenab, Mazda , Zheng, Wei , Cao, Guangwen , Riboli, Elio , Zeleniuch-Jacquotte, Anne , Shen, Hongbing

Mayo Clinic

Gut | November 24, 2012 | Volume: 63 | Issue: 1 | Pages: 152-160

10.1136/gutjnl-2012-303477 | PMID 23180869 Get It

Background and objective Survival of patients with pancreatic adenocarcinoma is limited and few prognostic factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify germline variants associated with survival in patients with pancreatic adenocarcinoma. Methods We analysed overall survival in relation to single nucleotide polymorphisms (SNPs) among 1005 patients from two large GWAS datasets, PanScan I and ChinaPC. Cox proportional hazards regression was used in an additive genetic model with adjustment for age, sex, clinical stage and the top four principal components of population stratification. The first stage included 642 cases of European ancestry (PanScan), from which the top SNPs (p≤10 −5 ) were advanced to a joint analysis with 363 additional patients from China (ChinaPC). Results In the first stage of cases of European descent, the top-ranked loci were at chromosomes 11p15.4, 18p11.21 and 1p36.13, tagged by rs12362504 (p=1.63×10 −7 ), rs981621 (p=1.65×10 −7 ) and rs16861827 (p=3.75×10 −7 ), respectively. 131 SNPs with p≤10 −5 were advanced to a joint analysis with cases from the ChinaPC study. In the joint analysis, the top-ranked SNP was rs10500715 (minor allele frequency, 0.37; p=1.72×10 −7 ) on chromosome 11p15.4, which is intronic to the SET binding factor 2 (SBF2) gene. The HR (95% CI) for death was 0.74 (0.66 to 0.84) in PanScan I, 0.79 (0.65 to 0.97) in ChinaPC and 0.76 (0.68 to 0.84) in the joint analysis. Conclusions Germline genetic variation in the SBF2 locus was associated with overall survival in patients with pancreatic adenocarcinoma of European and Asian ancestry. This association should be investigated in additional large patient cohorts.
Spectrum of Disorders Associated with Elevated Serum IgG4 Levels Encountered in Clinical Practice
Ryu, Jay H. , Horie, Ryohei , Sekiguchi, Hiroshi , Peikert, Tobias, Yi, Eunhee S. , Ryu, Jay H

Mayo Clinic

International Journal of Rheumatology | May 29, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/232960 | PMID 22693517 Get It

IgG4-related disease (IgG4-RD) is a recently described systemic fibroinflammatory disease associated with elevated circulating levels of IgG4 and manifests a wide spectrum of clinical presentations. Although serum IgG4 level has been described to be the most sensitive and specific laboratory test for the diagnosis of IgG4-RD, it is recognized that an elevated serum IgG4 level can be encountered in other diseases. In this study, we sought to identify the frequency of IgG4-RD and other disease associations in patients with elevated serum IgG4 levels seen in clinical practice. Among 3,300 patients who underwent IgG subclass testing over a 2-year period from January 2009 to December 2010, 158 (4.8%) had an elevated serum IgG4 level (>140 mg/dL). IgG4 subclass testing was performed for evaluation of suspected IgG4-RD or immunodeficiency. Twenty-nine patients (18.4%) had definite or possible IgG4-RD. Among those patients without IgG4-RD, a broad spectrum of biliary tract, pancreatic, liver, and lung diseases, as well as systemic vasculitis, was diagnosed. We conclude that patients with elevated serum IgG4 levels encountered in clinical practice manifest a wide array of disorders, and only a small minority of them has IgG4-RD.
Histopathologic Overlap between Fibrosing Mediastinitis and IgG4-Related Disease
Peikert, Tobias, Shrestha, Bijayee, Aubry, Marie Christine, Colby, Thomas V. , Ryu, Jay H. , Sekiguchi, Hiroshi , Smyrk, Thomas C. , Yi, Eunhee S. , Specks, Ulrich , Ryu, Jay H

Mayo Clinic

International Journal of Rheumatology | May 10, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-7

10.1155/2012/207056 | PMID 22654916 Get It

Fibrosing mediastinitis (FM) and IgG4-related disease (IgG4-RD) are two fibroinflammatory disorders with potentially overlapping clinical and radiological features. In this paper, we looked for histopathologic features of IgG4-RD and enumerated infiltrating IgG4-positive plasma cells within mediastinal tissue biopsies from FM patients. We identified 15 consecutive FM surgical mediastinal tissue biopsies between 1985 and 2006. All patients satisfied the clinical and radiological diagnostic criteria for FM. All patients had either serological or radiological evidence of prior histoplasmosis or granulomatous disease, respectively. Formalin-fixed paraffin-embedded tissue sections of all patients were stained for H&E, IgG, and IgG4. Three samples met the predefined diagnostic criteria for IgG4-RD. In addition, characteristic histopathologic changes of IgG4-RD in the absence of diagnostic numbers of tissue infiltrating IgG4-positive plasma cells were seen in a number of additional cases (storiform cell-rich fibrosis in 11 cases, lymphoplasmacytic infiltrate in 7 cases, and obliterative phlebitis/arteritis in 2 cases). We conclude that up to one-third of histoplasmosis or granulomatous-disease-associated FM cases demonstrate histopathological features of IgG4-RD spectrum. Whether these changes occur as the host immune response against Histoplasma or represent a manifestation of IgG4-RD remains to be determined. Studies to prospectively identify these cases and evaluate their therapeutic responses to glucocorticoids and/or other immunosuppressive agents such as rituximab are warranted.
Reconsidering the Paradigm of Cancer Immunotherapy by Computationally Aided Real-time Personalization
Kogan, Yuri , Halevi–Tobias, Karin, Elishmereni, Moran, Vuk‐Pavlović, Stanimir , Agur, Zvia

Mayo Clinic

Cancer Research | March 15, 2012 | Volume: 72 | Issue: 9 | Pages: 2218-2227

10.1158/0008-5472.can-11-4166 | PMID 22422938 Get It

Abstract Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized application of immune therapeutics would increase the efficacy of immunotherapy. Here, we developed a method to predict and enhance the individual response to immunotherapy by using personalized mathematical models, constructed in the early phase of treatment. Our approach includes an iterative real-time in-treatment evaluation of patient-specific parameters from the accruing clinical data, construction of personalized models and their validation, model-based simulation of subsequent response to ongoing therapy, and suggestion of potentially more effective patient-specific modified treatment. Using a mathematical model of prostate cancer immunotherapy, we applied our model to data obtained in a clinical investigation of an allogeneic whole-cell therapeutic prostate cancer vaccine. Personalized models for the patients who responded to treatment were derived and validated by data collected before treatment and during its early phase. Simulations, based on personalized models, suggested that an increase in vaccine dose and administration frequency would stabilize the disease in most patients. Together, our findings suggest that application of our method could facilitate development of a new paradigm for studies of in-treatment personalization of the immune agent administration regimens (P-trials), with treatment modifications restricted to an approved range, resulting in more efficacious immunotherapies. Cancer Res; 72(9); 2218–27. ©2012 AACR.